drugset / Trial / NCT06657859
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and learn about the long term effect of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2029-09
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLM101 | Unknown | 30 mg/kg | Intravenous |